The biggest attraction of Acrux for me, originally, was its large and diverse product pipeline. And for a while we got regular updates on progress with that, additions and removals from that, and so forth.
But in the last few years we've heard hardly a peep about anything except Axiron, and maybe Evamist. It really seems like management is just sitting on their hands waiting for the Eli Lilly takeover offer.
Add to My Watchlist
What is My Watchlist?
